<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02584868</url>
  </required_header>
  <id_info>
    <org_study_id>2011-006034-17</org_study_id>
    <nct_id>NCT02584868</nct_id>
  </id_info>
  <brief_title>Colloids in Pediatric Cardiac Surgery: Comparison Between a Balanced and a Non-balanced Colloid</brief_title>
  <acronym>COLCHIRCARD</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Queen Fabiola Children's University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Queen Fabiola Children's University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare the clinical efficacy and safety of Volulyte® and Voluven® during
      elective open-heart surgery in pediatric patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>peri-operative blood losses in ml/kg</measure>
    <time_frame>at the end of the surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>peri-operative blood losses in ml/kg</measure>
    <time_frame>48H post surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>peri-operative blood losses in ml/kg</measure>
    <time_frame>72h post surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total volume of blood products administered during and after surgery</measure>
    <time_frame>72H post surgery and at the end of the hospitalisation (expected average of 17 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Laboratory Assessment - APTT, PTT, INR, Fibrinogen, , creatinine, CRP and nitrated albumin, EXTEM &amp; FIBTEM on ROTEM</measure>
    <time_frame>at the end of cardiopulmonary by-pass and until Day 3 post surgery</time_frame>
    <description>APTT, PTT, INR, Fibrinogen, , creatinine, CRP and nitrated albumin EXTEM &amp; FIBTEM on ROTEM</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Cardiac Surgery</condition>
  <condition>Cardiopulmonary Bypass</condition>
  <arm_group>
    <arm_group_label>Volulyte</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational drug: HES 130/0.4 (6%) in an isotonic electrolyte solution (brand name=Volulyte®)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Voluven</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control drug: HES 130/0.4 (6%) in sodium chloride 0.9% (brand name=Voluven®)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution</intervention_name>
    <description>Peri-operative fluid replacement therapy (max 40ml/kg/day)</description>
    <arm_group_label>Volulyte</arm_group_label>
    <other_name>Volulyte</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxyethyl starch 130/0.4 in 0.9% sodium chloride</intervention_name>
    <description>Peri-operative fluid replacement therapy (max 40ml/kg/day)</description>
    <arm_group_label>Voluven</arm_group_label>
    <other_name>Voluven</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 28 days to 3 years old

          -  Planned cardiac surgery with cardiopulmonary by-pass

          -  signed informed consent

        Exclusion Criteria:

          -  Moribund patients (ASA 5)

          -  Jehovah Witnesses

          -  Pre-operative coagulation disorders

          -  Pre-operative renal insufficiency

          -  Pre-operative hepatic disorders

          -  Intra-cranial hemorrhage

          -  hypernatremia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>3 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Van der Linden, MDPhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HUDERF</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ariane Willems, MD</last_name>
    <phone>+3224773240</phone>
    <email>ariane.willems@huderf.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Universitaire Des Enfants Reine Fabiola</name>
      <address>
        <city>Brussels</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ariane Willems, MD</last_name>
      <phone>+3224773240</phone>
      <email>ariane.willems@huderf.be</email>
    </contact>
    <investigator>
      <last_name>Philippe Van der Linden, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ariane Willems, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Faraoni, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 3, 2013</study_first_submitted>
  <study_first_submitted_qc>October 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2015</study_first_posted>
  <last_update_submitted>February 21, 2017</last_update_submitted>
  <last_update_submitted_qc>February 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxyethyl Starch Derivatives</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

